| Contents | 5 |
|---|
| List of contributors | 6 |
|---|
| Preface to the first edition | 8 |
|---|
| Preface to the second edition | 9 |
|---|
| Introduction | 10 |
| Asthma | 10 |
|---|
| Mouse models | 11 |
| Guinea pig models | 17 |
| Rat models | 18 |
| Rabbit models | 21 |
| Canine models | 21 |
| Sheep models | 22 |
| Primate models | 23 |
| References | 26 |
| Introduction | 38 |
| Chronic obstructive pulmonary disease | 38 |
| In vivo modeling systems for chronic obstructive pulmonary disease | 38 |
|---|
| Elastase-induced lung inflammation and emphysema | 41 |
| Cigarette smoke-induced inflammation and lung destruction | 46 |
| Future directions | 55 |
| Conclusion | 56 |
| References | 57 |
| Introduction | 67 |
| Murine models of allergen-induced airway hyperresponsiveness and inflammation | 67 |
|---|
| Murine models of allergen-induced AHR and inflammation: functional assessments | 69 |
| Significance of murine models | 76 |
| References | 85 |
| Introduction | 92 |
| Skin inflammatory disorders | 92 |
|---|
| Atopic dermatitis models | 94 |
| Psoriasis models | 105 |
| Summary | 118 |
| References | 120 |
| Introduction | 128 |
| In vivo models of neurogenic inflammation | 128 |
|---|
| Neurogenic arterial vasodilatation and plasma extravasation | 131 |
| Mucus secretion | 134 |
| Motor effects in the airways and urinary tract | 136 |
| References | 137 |
| Introduction | 143 |
| Animal models of inflammatory bowel disease | 143 |
|---|
| Spontaneous or natural models | 147 |
| Immunological, bacterial and bacterial byproduct model | 153 |
| Animal models of physical injury | 155 |
| Genetically engineered models | 161 |
| Adoptive transfer models | 167 |
| Concluding remarks | 168 |
| References | 168 |
| Introduction | 181 |
| Preclinical models of vascular inflammation | 181 |
|---|
| Models of vascular inflammation | 184 |
| Conclusions | 194 |
| References | 194 |
| Index | 204 |
|---|
| The PIR-Series Progress in Inflammation Research | 209 |